Blueprint Medicines (LTS:0HOJ) ROE % Adjusted to Book Value : 8.49% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Blueprint Medicines ROE % Adjusted to Book Value?

Blueprint Medicines's ROE % for the quarter that ended in Mar. 2024 was 161.59%. Blueprint Medicines's PB Ratio for the quarter that ended in Mar. 2024 was 19.04. Blueprint Medicines's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was 8.49%.

Blueprint Medicines ROE % Adjusted to Book Value Historical Data

The historical data trend for Blueprint Medicines's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines ROE % Adjusted to Book Value Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-9.53

7.74

-8.53

-14.87

-3.66

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-17.94	-12.12	-13.87	-6.20	8.49

Competitive Comparison of Blueprint Medicines's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Blueprint Medicines's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blueprint Medicines's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's ROE % Adjusted to Book Value falls into.

Blueprint Medicines ROE % Adjusted to Book Value Calculation

Blueprint Medicines's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-157.13%	/	42.98
	=	-3.66%

Blueprint Medicines's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	161.59%	/	19.04
	=	8.49%

Blueprint Medicines ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines (LTS:0HOJ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (LTS:0HOJ) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

BPMC:USA 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines (LTS:0HOJ) Headlines

No Headlines